Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Nov 14;288(51):36717–36732. doi: 10.1074/jbc.M113.492876

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

FIGURE 11. — Overexpression of ASNA1, optineurin, or peripherin renders cell less vulnerable to MPP⁺ treatment. A, cellular lysates obtained from MN9D cells transiently transfected with or without the vector containing T7-ASNA1-FLAG, OPTN-V5, PERI-Myc, or shRNA target sequence for optineurin (shOPTN) were subjected to an immunoblot analysis using the indicated antibodies to confirm overexpression of each tagged protein or knockdown of OPTN. B–E, MN9D cells transiently transfected with T7-ASNA1-FLAG (B), OPTN-V5 (C), PERI-Myc (D), or shRNA target sequence for OPTN (shOPTN, E) were treated with 50 μm MPP⁺ for the indicated time periods. Viability was measured by the MTT reduction assay. Each bar represents the mean ± S.E. from three independent experiments. Blank represents the cells transfected with an empty vector. The shRNA sequences that target firefly luciferase (shLuc) were used for negative control. ***, p < 0.001; **, p < 0.01; *, p < 0.05.